NCT00552396View on ClinicalTrials.gov

An Open-label, Dose-escalation Safety and Tolerability Trial Assessing Anti-KIR (1-7F9) in Subjects With Multiple Myeloma

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

May 31, 2007

Primary Completion Date

January 31, 2011

Study Completion Date

January 31, 2011

Conditions
Multiple Myeloma
Interventions
DRUG

Anti-KIR (1-7F9)

human monoclonal antibody

Trial Locations (4)

10029

Mont Sinai Medical Center, New York

43210

Ohio State University Medical Center, Columbus

46202

Indiana University Cancer Center, Indianapolis

78229-4427

Cancer Therapy Research Center at UTHSCSA, San Antonio

Sponsors

Lead Sponsor

Innate Pharma
All Listed Sponsors
lead

Innate Pharma

INDUSTRY

NCT00552396 - An Open-label, Dose-escalation Safety and Tolerability Trial Assessing Anti-KIR (1-7F9) in Subjects With Multiple Myeloma | Biotech Hunter | Biotech Hunter